Department of Global Health, University of Washington, Seattle, Washington, USA.
J Virol. 2014 Jan;88(2):1354-65. doi: 10.1128/JVI.02361-13. Epub 2013 Nov 13.
A major challenge in the development of an HIV vaccine is that of contending with the extensive sequence variability found in circulating viruses. Induction of HIV-specific T-cell responses targeting conserved regions and induction of HIV-specific T-cell responses recognizing a high number of epitope variants have both been proposed as strategies to overcome this challenge. We addressed the ability of cytotoxic T lymphocytes from 30 untreated HIV-infected subjects with and without control of virus replication to recognize all clade B Gag sequence variants encoded by at least 5% of the sequences in the Los Alamos National Laboratory HIV database (1,300 peptides) using gamma interferon and interleukin-2 (IFN-γ/IL-2) FluoroSpot analysis. While targeting of conserved regions was similar in the two groups (P = 0.47), we found that subjects with control of virus replication demonstrated marginally lower recognition of Gag epitope variants than subjects with normal progression (P = 0.05). In viremic controllers and progressors, we found variant recognition to be associated with viral load (r = 0.62, P = 0.001). Interestingly, we show that increased overall sequence coverage, defined as the overall proportion of HIV database sequences targeted through the Gag-specific repertoire, is inversely associated with viral load (r = -0.38, P = 0.03). Furthermore, we found that sequence coverage, but not variant recognition, correlated with increased recognition of a panel of clade B HIV founder viruses (r = 0.50, P = 0.004). We propose sequence coverage by HIV Gag-specific immune responses as a possible correlate of protection that may contribute to control of virus replication. Additionally, sequence coverage serves as a valuable measure by which to evaluate the protective potential of future vaccination strategies.
在开发 HIV 疫苗方面,一个主要的挑战是应对循环病毒中发现的广泛序列变异性。诱导针对保守区域的 HIV 特异性 T 细胞反应和诱导识别大量表位变体的 HIV 特异性 T 细胞反应都被提出作为克服这一挑战的策略。我们使用伽马干扰素和白细胞介素-2(IFN-γ/IL-2)荧光斑点分析,研究了 30 名未经治疗的 HIV 感染者的细胞毒性 T 淋巴细胞(CTL)识别至少 5%洛斯阿拉莫斯国家实验室 HIV 数据库(1300 个肽段)中编码的所有 B 群 gag 序列变体的能力,这些 CTL 来自有或无病毒复制控制的患者。虽然两组的靶向保守区域相似(P=0.47),但我们发现病毒复制控制良好的患者对 gag 表位变体的识别略低于正常进展患者(P=0.05)。在病毒血症控制器和进展者中,我们发现变体识别与病毒载量相关(r=0.62,P=0.001)。有趣的是,我们表明,总体序列覆盖率(通过 gag 特异性库靶向的 HIV 数据库序列的总体比例)的增加与病毒载量呈负相关(r=-0.38,P=0.03)。此外,我们发现序列覆盖率,而不是变体识别,与增加识别一组 B 群 HIV 创始病毒相关(r=0.50,P=0.004)。我们提出 HIV gag 特异性免疫反应的序列覆盖率作为可能的保护相关因素,可能有助于控制病毒复制。此外,序列覆盖率是评估未来疫苗接种策略保护潜力的一个有价值的指标。